Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyprexa Goes Generic: Teva Fills "Basket" Of Doses With Dr. Reddy's Deal

Executive Summary

Teva Pharmaceutical Industries greeted the patent expiration of Lilly’s Zyprexa (olanzapine) by launching all six tablet doses of the antipsychotic, thanks to an agreement with Dr. Reddy’s Laboratories Ltd.
Advertisement

Related Content

Teva’s U.S. Generic Sales Rebound With Late-Year Launches, Ranbaxy Lipitor Deal
Ranbaxy Likely To Go Solo For Lipitor Launch; FDA Closer To Resolving Manufacturing Issues
Lilly Prepares For Zyprexa Expiration; Increases R&D Spend
Lilly Prepares For Zyprexa Expiration; Increases R&D Spend

Topics

Advertisement
UsernamePublicRestriction

Register

PS053896

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel